PNA Blocker Kit for Specific rpoB Drug-Resistance Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current molecular testing methods for drug-resistant TB are complex, require expensive equipment, have high costs, and suffer from insufficient detection sensitivity and specificity, with non-specific amplification from wild-type templates leading to false positive results.
Innovation Solution
A combination of peptide nucleic acid (PNA) blockers is used to comprehensively cover mutation sites in the rpoB gene, matching wild-type sequences to suppress non-specific amplification in quantitative PCR, accompanied by mutation detection probes to accurately identify specific mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional culture-based drug sensitivity testing is used, then detection accuracy can be maintained, but detection time is excessively long (about 1 month)
Solution Approach 1:
The patent replaces the traditional culture-based mechanical/biological testing system with a molecular diagnostic system using quantitative PCR. This substitution enables rapid detection of drug resistance mutations in the rpoB gene within hours rather than months, while maintaining or improving detection accuracy through direct genetic analysis.
Solution Approach 2:
The patent transitions from phenotypic detection (culture-based observation of bacterial growth characteristics) to genotypic detection (molecular analysis of DNA sequences). This phase transition from physical/biological observation to molecular analysis dramatically reduces detection time while providing more precise and reliable results.
2Loss of time
If rapid liquid culture system is used, then detection time is shortened to 8-10 days, but equipment complexity and cost increase
Solution Approach 1:
The patent replaces the rapid liquid culture system's complex automated culture equipment with a molecular PCR-based system. This substitution eliminates the need for specialized culture equipment, automated incubators, and complex data analysis systems, while achieving even faster detection times through direct DNA analysis.
Solution Approach 2:
The patent employs disposable PCR reaction mixtures, primers, and probes that can be easily discarded after use, eliminating the need for expensive, complex, and difficult-to-maintain specialized equipment. The methodology uses consumable reagents rather than capital equipment.
3Productivity
If molecular diagnostic methods are used, then detection speed is greatly improved (within one day), but detection specificity is reduced due to non-specific amplification from wild-type templates
Solution Approach 1:
The patent introduces PNA (peptide nucleic acid) blockers as intermediary molecules that specifically bind to wild-type rpoB gene sequences. These blockers act as mediators that prevent non-specific amplification by blocking the binding of primers to wild-type templates, thereby eliminating false positive results while maintaining rapid detection capability.
Solution Approach 2:
The patent applies preliminary anti-action by using PNA blockers to preemptively prevent non-specific amplification before it can occur. The blockers are added to the PCR reaction mixture and bind to wild-type sequences in advance, creating a protective effect that prevents false positive results from arising during the amplification process.
4Measurement precision
If PNA blockers are added to suppress non-specific amplification, then detection specificity is improved, but reaction complexity increases
Solution Approach 1:
The patent optimizes the concentration and sequencing of PNA blockers to achieve the desired specificity without excessive complexity. By carefully controlling the amount of blocker added and the order in which components are introduced, the methodology achieves high specificity while maintaining relatively simple reaction conditions and straightforward protocol steps.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PNA blockers significantly enhance detection specificity, reducing false positives and improving the accuracy of drug resistance testing for Mycobacterium tuberculosis.
Implementation Method 1
A combination of peptide nucleic acid (PNA) blockers is used to comprehensively cover mutation sites in the rpoB gene, matching wild-type sequences to suppress non-specific amplification in quantitative PCR
Data Source
AI summary
A combination of blockers for detecting drug resistance of Mycobacterium tuberculosis, including a first peptide nucleic acid (PNA) blocker, a second PNA blocker, a third PNA blocker, and a fourth PNA blocker. The first PNA blocker covers codons 511 and 513 of rpoB gene. The second PNA blocker covers codon 516 of rpoB gene. The third PNA blocker covers codon 526 of rpoB gene. The fourth PNA blocker covers codons 531 and 533 of rpoB gene. The sequences of the first, second, third, and fourth PNA blockers respectively match the wild-type sequences of the corresponding regions of rpoB gene. A kit and method for detecting drug resistance of Mycobacterium tuberculosis are also provided.